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Abstract 
ABSTRACT 
The clinical aspect of measuring the level of anti-nucleosome antibodies in patients with 
systemic lupus erythematosus (SLE) has been well established and it is claimed that their 
presence is associated with the disease activity. The overall aim of this study was to 
measure the level of anti-nucleosome· antibodies in the SLE patients, to determine the 
sensitivity as well as the specificity of these antibodies in the diagnosis of the disease. The 
evaluation of the relationship between the levels of anti-nucleosome antibodies, the disease 
activity as well as and other markers (anti-dsDNA antibodies, C3, C4 and CRP) were also 
compared and assessed. 
In this cross sectional study, all patients were selected from Hospital Universiti Sains 
Malaysia (HUSM), who were either attending the medical specialist's clinic or have been 
admitted to the medical wards. Ninety SLE patients, forty-five other connective tissue 
diseases (e.g., rheumatoid arthritis, mixed connective tissue disease, scleroderma, 
Raynaud's syndrome and Sjogren's s~drome) and ninety normal controls were tested for 
anti-nucleosome antibodies by enzyme linked immunosorbent assay (ELISA), anti-dsDNA 
and ANA by Immunofluorescence (IF), C3, C4 and CRP by immunoturbidometry 
techniques. SLE diseases activity was evaluated by using SLE-Disease Activity Index 
(SLEDAI) score. A patient is defined as having active SLE when SLEDAI score is more 
than 5.0 
xvu 
Abstract 
Out of 90 SLE patients, anti-nucleosome antibodies were positive in 52% of patients, 
whereas these antibodies were positive in 7% of patients with other connective tissue 
diseases. The median concentration of anti-nucleosome antibodies was significantly 
different between SLE patients and other connective tissue diseases. None of the normal 
controls was found to be positive for these antibodies. Anti-dsDNA antibodies were 
positive in 3 7% SLE patients, whereas these antibodies were positive in 8% of patients with 
other connective tissue diseases. None of the normal controls was found to be positive for 
these antibodies. ANA was found to be positive in 81% SLE patients, in 61% of patients 
with other connective tissue diseases and 7% in normal controls. Anti-nucleosome 
antibodies had a sensitivity of 52%, whereas anti-dsDNA antibodies had a sensitivity of 
37%. The specificity of anti-nucleosome and anti-dsDNA antibodies was 98% and 97% 
respectively. ANA had sensitivity and specificity of 81% and 75% respectively. Anti-
nucleosome antibodies were positive in 98% of patients with active SLE, whereas these 
antibodies were positive in 14% of patients with inactive SLE. The median concentration of 
anti-nucleosome antibodies was significantly different between active and inactive SLE 
patients. Anti-dsDNA antibodies were found to be positive in 61% of patients with active 
SLE and in 16% of patients with inactive SLE. Anti-nucleosome antibodies had a stronger 
correlation than anti-dsDNA antibodies with SLEDAI score. The median concentration of 
C3 and C4 was significantly different between active and inactive SLE patients, and 
showed an inverse and significant correlation with SLEDAI score, whereas the median 
concentration of CRP was not significantly different between active and inactive SLE. 
XVlll 
Abstract 
In conclusion, anti-nucleosome antibodies test is a recently developed test that may help in 
diagnosis of SLE patients. Anti-nucleosome antibodies are highly sensitive and specific for 
the diagnosis of SLE, especially when the anti-dsDNA antibodies are absent. Thus anti-
nucleosome antibodies test can be a better tool for the diagnosis of SLE. Anti-nucleosome 
antibodies have a stronger and significant correlation with SLEDAI score than other 
traditional disease activity markers. Therefore, it can be a useful and additional disease 
activity marker to other laboratory tests that can help in the assessment SLE disease 
activity. 
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Abstrak 
ABSTRAK 
ANTIBODI ANTI-NUKLEOSOM SEBAGAI PETANDA AKTIVITI DALAM 
PENYAKIT SYSTEMI LUPUS ERYTHEMATOSUS 
Pengukuran paras antibodi anti-nukleosom dalam pesakit SLE telahpun diselidik pada 
peringkat klinikal dan ianya membuktikan bahawa kehadiran antibodi ini berkaitan dengan 
aktiviti penyakit itu sendiri. Tujuan utama kajian ini adalah untuk mengukur paras antibodi 
anti-nukleosom pada pesakit SLE dan. mengesan sensitiviti serta spesifisiti antibodi anti-
nukleosom dalam diagnosis SLE. Selain itu, penyelidikan di antara hubungan paras 
antibodi, aktiviti penyakit dan petanda aktiviti penyakit lain (antibodi anti-dsDNA, C3, C4 
dan CRP) juga turut dibanding dan diperukurkan. 
Dalam kajian secara rambang, semua pesakit dipilih dari HUSM, ini termasuklah mereka 
yang hadir di klinik pakar perubatan dan yang telah dimasukkan ke wad. Seramai 90 
pesakit SLE telah dipilih dalam kajian ini, 45 adalah pesakit yang berhubung dengan 
penyakit tisu penghubung ( seperti, rheumatoid arthritis, penyakit tisu penghubung 
campuran, scleroderma, sindrom Raynaud dan sindrom Sjogren) dan 90 individu normal 
yang bertindak sebagai kawalan. Mereka ini telah diuji dengan ujian-ujian antibodi anti-
nukleosom dengan ELISA, anti-dsDNA dan ANA dengan IF, C3, C4 dan CRP 
menggunakan teknik immonoturbidometry. Aktiviti penyakit SLE telah dikaji dengan 
menggunkan skor (SLEDAI). Seseorang yang dikatakan mempunyai SLE aktif apabila 
paras SLEDAI melebihi 5.0. 
XX 
Abstrak 
Daripada 90 pesakit SLE, seramai 52% pesakit mempunyai antibodi anti-nukleosom yang 
positif manakala 7% pesakit daripada penyakit tisu penghubung yang lain. Konsentrasi 
median antibodi anti-nukleosom adalah berbeza diantara pesakit SLE dan penyakit tisu 
penghubung yang lain. Antibodi anti-dsDNA adalah 37% positif pada pesakit SLE, 
manakala 8% lagi positif pada penyakit tisu penghubung yang lain. Tidak seorangpun 
individu normal positif kepada antibodi anti-dsDNA. ANA didapati positif dalam 81% 
pesakit SLE,61% pada penyakit tisu penghubung dan 7% pada kawalan normal. Antibodi 
anti-nukleosom mempunyai sensitiviti sebangak 52%, sementara antibodi anti-dsDNA 
mempunyai sensitiviti sebanyak 37%. Spesifisiti antibodi anti-nukleosom dan anti-dsDNA 
adalah 98% dan 97% . ANA mempunyai sensitiviti dan ketepatan sebanyak 81% dan 75%. 
Antibodi anti-nukleosom adalah positif iaitu sebanyak 98% pada pesakit SLE yang aktif, 
sementara antibodi ini positif iaitu sebanyak 14% pada pesakit SLE yang tidak aktif. 
Konsentrasi median antibodi anti-nukleosom adalah berbeza diantara pesakit SLE aktif dan 
tidak aktif, sementara antibodi anti-dsDNA telah ditemui positif sejumlah 61% daripada 
pesakit SLE aktif dan 16% pesakit SLE yang tidak aktif. Antibodi anti-nukleosom 
mempunyai perkaitan yang kuat dengan antibodi anti-dsDNA melalui skor SLEDAI. 
Konsentrasi median C3 dan C4 adalah berbeza diantana pesakit SLE yang aktif dengan 
yang tidak aktif, dan ini menunjukkan perkaitan terhadap skor SLEDAI, sementara itu, 
konsentrasi median CRP tidak menunjukkan sebarang berbezaan diantara pesakit SLE aktif 
dan yang tidak aktif. 
Kesimpulannya, ujian antibodi anti-nukleosom telah berkembang dan ini akan membantu 
dalam diagnosis pesakit SLE. Antibodi anti-nukleosom mempunyai sensitiviti yang tinggi 
dan ketepatan dalam diagnosis SLE, terutama apabila ketiadaan antibodi anti-dsDNA. 
XXI 
Abstrak 
Maka, antibodi anti-nukleosom merupakan ujian altematif yang boleh digunakan dalam 
diagnosis SLE. Antibodi anti-nukleosom mempunyai perkaitan yang kuat dan hubungan 
melalui skor SLEDAI berbanding dengan petanda aktiviti penyakit tradisional yang lain. 
Oleh itu, ianya boleh digunakan petanda aktiviti penyakit bagi tujuan ujian makmal dalam 
membantu mengenalpasti aktiviti penyakit SLE. 
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Introduction 
INTRODUCTION 
1. Autoimmunity and autoimmune diseases 
Autoimmunity is defined as a condition when an individual's immune system begins reacts 
adversely against its own tissues. The primary cause is a loss of tolerance to one's own 
tissue antigens. Normally, the immune system is able to distinguish self tissue antigens 
from foreign non-self tissue antigens. Hence, the essential mechanism of autoimmunity is 
the failure of the immune system to recognize its own tissues as self and to react to these as 
foreign antigens (Brostoff and Howell, 1992). 
Many factors participate in the generation of autoimmunity. Helper T cells control the 
immune response to protein antigens: defects in this cell population may lead to high 
affinity autoantibody production reactivity to self antigens. These phenomena are often 
linked to certain major histocompatibility complex (MHC) loci leading to the production of 
autoimmunity and various immunologi~ alterations may consequently lead to autoimmune 
diseases (Blackman eta/., 1990). 
Autoimmune diseases affect 5-7% of the population, and can be either organ-specific or 
non-organ specific (systemic autoimmune disease). In organ-specific autoimmune disease, 
such as autoimmune thyroiditis, the immune response is directed to a target antigen unique 
to a single tissue or organ, so that the autoimmune destruction could be largely limited to 
that organ. 
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In non-organ specific autoimmune disease, such as systemic lupus erythematosus (SLE) 
and rheumatoid arthritis, the response is directed towards a broad range of target antigens 
and involves a number of organs and tissues (Brostoff and Howell, 1992). Non-organ 
specific autoimmune diseases, which also are called connective tissue or rheumatic diseases 
have clinical importance and they represent a major group of autoimmune diseases. The 
diffuse connective tissue diseases include SLE, rheumatoid arthritis, Sjogren's syndrome, 
scleroderma, Raynaud's syndrome, mixed connective tissue disease (MCTD) and 
polymyositis (Alarcon eta/., 1991). 
Each of the connective tissue diseases has its own pattern of clinical features, time course, 
location of lesions, auto-antibody reactivity and immunopathologic mechanisms. There is 
considerable overlap of pathologic features within the connective tissue disease group and a 
given patient may have features of several of the connective tissue diseases (overlap 
syndromes) (Tan, 1989). Many connective tissue diseases share common signs and 
symptoms, which frequently makes the diagnosis of a specific connective tissue disease 
difficult. Current clinical practice relies heavily on serologic testing for the prompt and 
accurate diagnosis of connective tissue diseases (table 1.1 ). Serologic testing is used to 
support the medical history and physical examination and in some cases to monitor disease 
activity (Barland and Lipstein, 1996). 
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Table 1.1 Autoimmune diseases and respective autoantibodies 
Disease 
SLE 
Scleroderma 
Sjogren's syndrome 
Raynaud's syndrome 
Autoantibodies directed against: 
Nuclear antigens, DNA, Sm 
Nuclear antigens, Sci 1 
Nuclear antigens, SS-A, SS-B 
Extractable nuclear antigens (RNP) 
MCTD Extractable nuclear antigens (RNP) 
Rheumatoid arthritis Fe portion of IgG (rheumatoid factor) 
Cited from the textbook of autoimmune diseases, page: 301 (Deodhar, 1990) 
A major clinical problem is distinguishing SLE from other connective tissue diseases. 
Multisystem involvement is a common feature of all theses conditions, and all frequently 
present with a mixture of systemic symptoms (Barland and Lipstein, 1996). Historically, 
laboratory tests have been developed to diagnose SLE, whereby anti-nucleosome antibodies 
stand as the most recent diagnostic criteria. 
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1.1. Systemic lupus erythematosus 
Systemic Lupus Erythematosus (SLE) is one of the many autoimmune disorders. It is a 
chronic, often life long, autoimmune disease characterized by inflammation and damage of 
various body tissues including joints, skin, kidneys, heart, lungs, blood vessels and brain. 
People with the disease may present with many different symptoms and some of the most 
common symptoms at onset are extreme fatigue, painful or swollen joints, fever, skin 
rashes and renal manifestations (NIAMS, 2002). 
1.1.1. Epidemiology 
Primarily SLE is a disease of young women of childbearing age between 15 and 40 years 
old and female to male ratio is about 9: 1 during this period. However the onset of disease 
can range from infancy to old age. SLE affects approximately 1 in 2000 individuals in the 
general population, although the prevalence varies with race, ethnicity and the 
socioeconomic status (Ward et a/., 1995). Estimation of the incidence of SLE in United 
States varies; it is reported that it was 124 cases per 100 000 (Hochberg et a/., 1995) while 
in another study the incidence in the United States and continental Europe ranged from 14.6 
to 68/100,000 (Bongu et al., 2002). However, some reports indicate that because of 
improved diagnostic measures, the incidence of SLE is increasing. For example, in a study 
covering a span of greater than 40 years found that the pooled incidence of SLE had more 
than tripled from 1.51/100,000 during 1950-1979 to 5.56 /100,000 during 1980-1992 
(Uramoto eta/., 1999). 
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In a recent review of I9 studies published from I995 to 2000, Ruiz-Irastorza et a/., (200 I) 
reported an even higher incidence rate (7.3/IOO 000). The incidence of SLE is about 3 times 
higher in African American women than in white women (McCarty eta/., 1995 and Petri, 
I998). It has been shown that Blacks are indeed more prone to develop SLE compared to 
Caucasians (Fessel, 1988). In the United States, morbidity and mortality appears to be 
greater among Hispanic than among whites (Bongue et a/., 2002). 
SLE is also common among Asian and Chinese and an increased prevalence of SLE has 
been noted in people of oriental races (Frank, I980). The highest rate is shown in African 
Caribbean (207 /1 00,000), followed by Asian ( 48.8/1 00,000) and Whites (20.3/I 00,000) 
(Molokhia eta/., 2001 and Hopkinson eta/., I994). Although SLE is not prevalent in men, 
male patients who develop the disease, renal, neurological, hematological and vascular 
involvements are usually more severe compared to women (Mok et a/., 1999). 
1.1.2. Aetiology of SLE 
The aetiology of SLE remains unknown. However, genetic predisposition, sex hormones 
and environmental factors may play important roles in the pathogenesis of SLE (McCarty 
et al., I995 and Petri, 1998). 
1.1.2 (a). Genetic factors 
The familial prevalence of SLE is estimated to be I 0%, and siblings to SLE patients have 
an increase risk of developing SLE compared to the general population. The role of 
heredity is further supported by the concordance rate of 24-58% in monozygotic twins 
(Hahn, 1998). 
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There is evidence for an association between SLE and the major histocompatibility 
complex (MHC class II and III regions on chromosome 6). Furthermore, there is a strong 
association between autoantibody production, such as anti-SSA/Ro antibody and anti-
SSB/La antibody, and the MHC class II subsets HLADR2 and DR3. Associations are also 
seen between SLE and complement deficiencies (Clq, C2 and C4), IL-10 promoter 
polymorphism, and most recently programmed cell death I gene (PDCD I) polymorphism 
(Sell and Max, 200 I). 
1.1.2 (b). Environmental and hormon,al factors 
• Ultraviolet (UV) radiation 
Nearly three quarters of the SLE patients report photosensitivity, and UV radiation induce 
skin lesions in these patients. Systemic symptoms can also be induced by sunlight 
exposure, although the exact relationship between UV exposure and disease activity is 
difficult to demonstrate (Osmola eta/., 2004). 
• Drugs 
A number of drugs have been reported to induce SLE or drug-induced lupus (DIL). The 
high-risk drugs reported to induce DIL are procainamide and hydralazine, followed by 
quinidine, chlorpromazine, sulfasalazine and penicillamine (Osmola eta/., 2004). 
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• Infectious agents 
Both viruses and bacteria have been suspected to be involved in the initiation of SLE. 
Among viruses, especially Epstein-Barr virus, cytomegalovirus and retroviruses may be 
linked to the development of SLE. Elevated antibody titers to several viruses have been 
reported in SLE patients (Cooper et al., 1998). 
• Hormones 
Sex hormones play a part in the pathogenesis of SLE. An increased frequency of SLE 
among females is believed to be due to endogenous estrogens and androgens (Cooper eta/., 
1998). Some studies have found that exogenous exposure to estrogen, either through oral 
contraceptive (Sanchez-Guerrero et a/., 1997) or oestrogen replacement therapy (Sanchez-
Guerrero et a/., 1995), may increase the incidence of SLE. 
• Other environmental risk factors · 
A number of additional risk factors for SLE have been described. Smoking, severe 
emotional/physical stress, hypertension, drug allergy, sun-reactive skin type and intake of 
alfalfa seeds are all reported to increase the risk of developing SLE (Shapiro eta/., 2004). 
1.1.3. Immunopathogenesis 
SLE is characterized by alterations in many different parts of the immune system, but 
patients may share some common characteristics; a loss of tolerance and the production of 
pathogenic autoantibodies with immune complex formation. 
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1.1.3 (a). Loss of tolerance 
A fundamental process in autoimmune disease is the breakdown in immunological 
tolerance either centrally or peripherally. Central tolerance involves thymic deletion of self 
reactive cells and upregulation ofT -cells with low affinity to self-MHC. The peripheral T-
cell tolerance includes anergy (loss of co-stimulatory signals), deletion or suppression of 
reactive T -cells and ignorance of self antigens by the immune system. 
Failure to become tolerant to self antigens, cross-reactivity and molecular mimicry, 
development of auto-antibodies that cross-react with self antigens and polyclonal 
stimulation of naturally occurring autoantibody producing cells may underlie the initiation 
and maintenance of autoantibodies secretion (Manolios and Schrieber, 1997). 
1.1.3 (b). Cellular defect 
• T cells and B cells 
Nearly half of the SLE patients have decreased levels of circulating leukocytes, manifested 
as granulocytopenia and/or lymphocytopenia. The lymphocytopenia is primarily due to a 
decrease in T -cells and both CD4+ and CD8+ subsets seem to be affected (Horwitz et al., 
2002). However, the T -cells in SLE patients show signs of an in vivo activation and 
' 
autoreactive T -cells are considered to have an important role in the disease process 
(Horwitz, 2001). 
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The hallmark of the B-cell population In SLE is hyperactivity, with an increase of 
proliferation rates, elevated numbers of long-lived autoreactive B-cells and differentiation 
to plasma cells. This results in the production of autoantibodies and polyclonal 
hypergammaglobulinaemia (Liossist and Tsokos, 2002). 
• Dendritic cells (DC), monocytes/macrophages and natural killer (NK) cells 
Relatively little is known about the DC population in SLE patients, but a reduced number 
of circulating DC and an impaired T -cell stimulatory capacity by such DC have been 
demonstrated. 
In contrast, the number of monocytes among peripheral blood mononuclear cells (PMNC) 
from SLE patients is often increased, with an enhanced rate of spontaneous apoptosis 
(Scheinecker et a/., 2001 ). Interestingly, these monocytes may be induced to differentiate 
into DC by the presence of IFN-a in SLE serum. Such DC cells can function as Ag-
presenting cells (APC) that may explain the T cell activation seen in SLE (Santini eta/., 
2000). 
Natural killer (NK) cells are reduced both in number and in functional capability. This 
might be due to cytokine abnormality or high levels of circulating immune complexes 
binding to their Fe receptors and altering their function. The inability to clear circulating 
immune complexes by the reticuloendothelial system may increase tissue deposition and 
inflammation. The clearance occurs mainly in the liver (mediated by C3b receptors) and 
spleen (mediated by Fe receptors). 
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In SLE there is a defective splenic Fe receptor-mediated and hepatic C3b receptor-mediated 
clearance of immune complexes from the circulation. 
A number of cytokine abnormalities have been reported in SLE. These include decreased 
quantities of interleukin-1 (IL-l) and a low response and production of IL-2 by T -cells. 
There is an elevation of several cytokines such as IL-4, IL-5 and IL-6, which control B-cell 
' 
differentiation and antibody production during active disease (Hahn, 1980). 
1.1.4. Auto-antibodies and immune complexes 
Auto-antibodies can be detected in healthy individuals, although these natural 
autoantibodies are usually of the low affinity IgM isotype. They do not undergo maturation 
and do not cause autoimmune diseases or tissue damage (Liossist and Tsokos, 2002). 
The auto-antibodies production in SLE is thought to be of pathogenic relevance, mainly by 
the formation of immune complexes, and deposition in target tissues such as glomeruli, 
heart, skin and vessels. The deposited immune complexes then participate in inflammatory 
processes involving complement activ~tion, eventually causing tissue damage. In addition, 
immune complexes may have other properties, such as activation of auto-antibody 
production (Leadbetter eta/., 2002) and these autoantibodies can also interfere with normal 
cellular functions and contribute to disease manifestations (Cho eta/., 2002). 
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1.1.5. Clinical manifestations 
1.1.5 (a). Constitutional manifestations 
I 
The constitutional signs and symptoms of SLE often include fever, malaise, weight loss, 
symmetrical arthralgia, myalgia and headache (Greenberg, 1999).Among the most serious 
features of SLE are persistent fever and weight loss. 
1.1.5 (b). Musculoskeletal manifestations 
Over 90 percent of SLE patients have polyarthralgias or polyarthritis, which are the most 
common reason whereby SLE patients seek medical attention. Small joints of the hand and 
wrist are usually affected. Soft tissue and tendon thickening causes swelling of these joints 
but the effusion is small unlike in rheumatoid arthritis, in which the swelling would be 
pronounced and bones may be defonned. SLE arthropathy is usually not erosive or 
destructive to bone (Cronin, 1988). 
1.1.5 (c). Mucocutaneous manifestations 
More than 90 percent of patients with SLE eventually have cutaneous manifestations of the 
disease, including malar rash, discoid rash and alopecia. Approximately two-thirds of SLE 
patients have photosensitivity, defined as a skin rash due to an unusual reaction to sunlight 
(Laman and Provost, 1994). Skin manifestations of SLE can be acute, subacute or chronic. 
Some acute manifestations include bullous lesions and generalized erythema, which may or 
may not be photosensitive in nature (Sontheimer and Gilliam, 1992). 
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The most characteristic clinical feature of subacute cutaneous lesion is superficial, non-
indurated and non-scarring photosensitivity-induced skin rash (David-Bajar eta/., 1992). In 
chronic cutaneous SLE, patients may have a discoid rash with scarring. Oral, nasal and 
other mucus membrane lacerations may occur (Nguyen and Foster, 1998). Raynaud's 
syndrome occurs in 1 0- 45 % of SLE patients, is the result of vasospasm and muscular 
damage and presents with the classical white, blue and red color changes in the fingers 
(Hahn, 1997). Alopecia is observed in up to 45 % of SLE patients at some time in the 
disease or it can occur with some therapies for SLE. Hair loss may be diffuse or patchy 
associated with discoid lesions (Hahn, 1998). 
1.1.5 (d). Serositis 
Inflammatory serositis of the pleura, peritoneum and pericardium occur in 25 % of SLE 
patients (Manolios and Schrieber, 1997). Patients may develop large pleural effusions, 
pericardia! effusion or ascites. These effusions are typically inflammatory and exudative. 
1.1.5 (e). Hematological manifestations 
Anemia, leucopenia and thrombocytopenia are frequent manifestations of SLE and these 
patients often have normocytic normochromic anemia. Coombs test is frequently positive 
and circulating anti-erythropoietin antibodies are reported as a possible mechanism of 
anemia (Tzioufas et a/., 1997). Leucopenia with white blood cell (WBC) counts less than 
4000/mm3 or lymphopenia with lymphocyte counts less than 1500/mm3 on two or more 
occasions are part of the diagnostic criteria of SLE (Mills, 1994). 
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Thrombocytopenia with a platelet counts less than 1 OO,OOO/mm3 in the absence of other 
causes is found in up to 25 % of SLE patients. However thrombocytopenia is often a 
marker of severe disease with poor prognosis (Reveille et. a/, 1990). 
1.1.5 (f). Renal involvement 
The kidney is the most commonly involved organ in patients with SLE and is a major cause 
of mortality and morbidity. Several studies show evidence of nephritis in approximately 50-
70 % of renal biopsies from SLE patients (Golbus and McCune, 1994). Several 
demographic, ethnic, immunologic and genetic factors have been associated with nephritis 
(Hopkinson et a/., 2000; Seligman et a/., 2002). The clinical manifestations of lupus 
nephritis that can be seen in SLE patie~ts are asymptomatic haematuria and/or proteinuria, 
nephrotic syndrome or chronic renal failure. The renal involvement caused by auto-
antibodies or accumulation of immune complexes containing anti-dsDNA antibodies in the 
kidney (Huong et a/., 1999). The World Health Organization (WHO) has classified lupus 
nephritis into six classes {Table 1.2). 
Table 1.2 World Health Organization classification of lupus 
Class 
I 
II 
III 
IV 
v 
VI 
Histology 
Normal 
Mesangial lupus nephritis 
Focal prolifer~tive lupus nephritis 
Diffuse proliferative glomerulonephritis 
Membranous glomerulonephritis 
Glomerulosclerosis 
(Huong eta/., 1999) Medicine. 78: 148-166. 
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Excellent 
Good 
Moderate 
Poor 
Moderate 
Poor 
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1.1.5 (g). Central Nervous System (CNS) involvement 
Neuropsychiatric involvement of patients with SLE ranges from headache to CNS 
vasculitis (Boumpas et al., 1995). Other unusual manifestations of CNS lupus include 
Parkinsonism, cerebellar ataxia, pseudotumor cerebrae, hypothalamic dysfunction, aseptic 
meningitis, myasthenia-like syndrome, Eaton-Lambert syndrome and thrombotic 
thrombocytopenic purpura. Peripheral nervous system involvement of SLE is also noted in 
10 % of patients and includes sensory or motor myopathies, Guillain Barre-like syndrome 
and mononeuritis multiplex. 
The pathogenesis of neuropsychiatric SLE includes vasculitis-induced blood vessel 
occlusion, antibodies against brain tissue, hypercoagulable status due to anti-phospholipid 
antibodies (aPL) and other secondary causes such as infection, metabolic derangement and 
side effects of drugs that are used for treatment of SLE (Boumpas et a/., 1995). Recently, 
circulating anti-ribosomal P antibodies have been found in many lupus patients with 
neuropsychiatric manifestations (Y oshio et a/., 2005). 
1.1.5 (h). Cardiac manifestations 
SLE affects the heart leading to pericarditis, myocarditis, coronary artery disease and 
endocarditis. Pericarditis is the most common cardiac manifestation of SLE, occurring in 
about 20-30 %of patients and usually presents with mild anterior chest pain (Petri eta/., 
1992). Myocarditis is suspected when SLE patients have cardiomegaly, arrhythmias, or 
conduction defects and they usually co-exist with pericarditis in the active phase of SLE. 
Sterile vegetation of the heart valves or Liebman Sacks' endocarditis is a less common 
manifestation of SLE (Petri eta/., 1992). 
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Gentile et al., (2000), found that 19' out of 91 SLE patients (20.8%) had pericardia! 
effusion. Valvular involvement occurred in 39 patients (42.8%) whereby moderate to 
severe degree was more frequent in the group with aPL. Regional wall motion 
abnormalities were observed in 8 patients (8.8%). On rare occasions, SLE can be 
accompanied by coronary artery vasculitis and can result in myocardial infarction. There is 
an increased incidence of atherosclerotic heart disease (Urowitz, et al., 2000) and this may 
be initiated by immune complex deposition, but certainly it is aggravated by chronic steroid 
therapy, which can produce hyperlipidemia and hyperglycemia. 
1.1.5 (i). Pulmonary manifestations 
The pulmonary manifestations of SLE include pneumonitis, pulmonary hemorrhage, 
pulmonary hypertension and embolism. Lupus pneumonia is a clinical dilemma that 
requires careful diagnosis because it must be differentiated from infectious pneumonia. 
Pulmonary hemorrhage from vasculitis is associated with 50-60% mortality rate and is a 
true medical emergency (Schwab et al., 1993). Pulmonary hypertension is more commonly 
associated with long-term restrictive lung diseases and Raynaud's syndrome. 
In a retrospective study performed by Mochizuki et al., (1999), the types of pulmonary 
involvement found in SLE patients were pleuritis (9% ), interstitial pneumonia (8% ), 
pulmonary infarction (7%), infection. (4%), pulmonary hypertension (2%), restrictive 
dysfunction (28%) and reduced diffusion capacity (43%). 
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1.1.5 (j). Gastrointestinal manifestations 
Gastrointestinal symptoms in patients with SLE are relatively common and present as 
abdominal pain, anorexia and/or vomiting. Peritoneal inflammation is the most likely cause 
of gastrointestinal symptoms, but mesenteric vasculitis or pancreatitis are dangerous 
complications ofSLE (Gladman and Urowitz, 1997). 
1.1.5 (k). Ocular manifestations 
Ocular involvement in SLE can cause conjunctivitis and retinal lesions can occur. The 
retinal lesions are vasculitis and include white exudate ( cytoid bodies), hemorrhage, retinal 
edema and sometimes papilledema. These lesions are always associated with active SLE. 
Cytoid bodies occur in 10-20% of SLE patients (Nguyen and Foster, 1998). 
1.1.5 (l).Secondary anti-phospholipid antibody syndrome 
SLE patients have an increased incidence of secondary anti-phospholipid syndrome. This 
syndrome is defined as the co-occur:rence of thrombotic events and the presence of 
autoantibodies against the negatively charged phospholipids, such as lupus anti-coagulant, 
or anti-cardiolipin antibodies (Sinico eta/., 2002). Anti-phospholipid antibodies are part of 
a group of antibodies that are associated with problems relating to abnormal blood clotting 
leading to produces such as miscarriages, deep vein thrombosis, pulmonary emboli and 
strokes. This syndrome occurs more frequently in patients with a high titer of IgG 
anticardiolipin antibodies or lupus anticoagulant. 
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The mechanism of this prothrombotic diathesis is uncertain, but these auto-antibodies bind 
to target antigens on endothelial cells, platelets or coagulation factors producing a 
hypercoagulable state (Asherson, 1989). These auto-antibodies are found in some people 
with lupus and other autoimmune diseases and occasionally in people without any known 
disease. 
1.1.6. Laboratory tests for the diagnosis of SLE 
Diagnosis of SLE can be difficult and requires knowledge and awareness of the disease and 
good communication with the patient. A complete, accurate medical history, physical 
examination and results of laboratory tests are critical for diagnosis of this disorder 
(NIAMS, 2002). 
The LE cell test was a standard procedure to diagnose SLE. Almost for two decades an 
intensive research was performed to discover the specificity of antibodies that cause the LE 
cells phenomenon (Rekvig and Hannes ted, 1981 ). Today, laboratories have started using 
other tests which are more helpful in the diagnosis of SLE. One of these tests is the ANA 
test, commonly used to look for autoantibodies that react against components of nucleus. 
In suspected SLE patients, ANA is important as a screening test and it can be done by 
indirect immunofluorescence method (IF) or enzyme immunosorbent assay method 
(ELISA) (Tan, 1989). ANA is very sensitive for SLE and elevation of ANA titer to 1:40 or 
more is the most sensitive according to the American College of Rheumatology (ACR) 
diagnostic criteria. More than 99% of SLE patients have elevated ANA titers (Tan et al., 
1982). 
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However, ANA test is not specific for SLE and the most common reason for a positive 
ANA test in the absence of SLE is another connective tissue disease. Diseases often 
associated with a positive ANA test include Sjogren syndrome, scleroderma, rheumatic 
disease and juvenile rheumatoid arthritis (Sinico et. a/, 2002). Testing for antibody to anti-
dsDNA and anti-Sm antibody to Smith (Sm) antigen may be helpful in patients who have a 
positive ANA test but do not meet the full criteria for the diagnosis of SLE. 
Anti-dsDNA and anti-Sm antibodies, particularly in high titers, are highly specific for SLE, 
although their sensitivities are low. Therefore, a positive result helps to establish the 
diagnosis of the disease, but a negative result does not rule it out (Kavanaugh et a/., 2000). 
In addition, there are other blood tests which are helpful in diagnosis of SLE, e.g., anti-
ribonuclear protein (anti-RNP) antibody, anti-Ro (SS-A) antibody and anti-La (SS-B) 
antibody (Hochberg, 1997). However, hypocomplementemia and antibodies against Ro 
(SSA), La (SSB) and to phospholipids (anticardiolipin) are detectable in SLE as well as 
other connective tissue diseases (Weinstein eta/., 1983). 
Total serum hemolytic complement (CH50) and individual complement components (C3 
and C4) may be low in patients with active SLE (Weinstein et a/., 1983). However, for the 
diagnostic purpose, ANA and anti-dsDNA antibodies are more useful. Therefore a 
combination of anti-dsDNA, C3, C4, C- reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) assays provide useful information for its diagnosis (Enger, 2000). 
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The diagnosis of systemic lupus erythematosus is based on both clinical and laboratory 
criteria. The criteria set by the American College of Rheumatology (ACR) are most widely 
used {Tan et al., 1982 and Hochberg, 1997). A person is suspected to have SLE if she/he 
fulfills 4 out of the 11 criteria (Hochberg, 1997) {Tablel.3). 
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Criterion 
Malar rash 
Discoid rash 
Photosensitivity 
Oral ulcers 
Non-erosive arthritis 
Pleuritis or pericarditis 
Renal disorders 
Neurological disorders 
Hematologic disorders 
Immunologic disorders 
Positive ANA 
Table 1.3 ACR classification criteria for SLE 
Definition 
Fixed erythema, flat or raised, over the malar eminences and sparing the 
nasal folds 
Erythematous raised patches with adherent keratotic scaling and 
follicular plugging: atrophic scarring may occur in older lesion 
Skin rash as a result of unusual reaction to sunlight by history or on 
physical exam 
Oral or nasopharyngeal ulceration observed by a physician are usually 
painless 
Involving two or more peripheral joints, characterized by tenderness, 
swelling or effusion 
a. Pleuritis- convincing history of pleuritic pain or rub heard 
by a physician or evidence of pleural effusion 
b. Pericarditis- documented by electrocardiogram or rub or 
evidence of pericardia! effusion 
a. Persistent proteinuria > 0.5 gm per day OR 
b. Cellular cast that may be red cells, hemoglobin, granular, 
tubular or mixed 
a. Seizure in the· absence of offending drugs or known 
metabolic derangement; e.g. uremia, ketoacidosis or 
electrolyte imbalance OR 
b. Psychosis in the absence of offending drugs or known 
metabolic derangement; e.g. uremia, ketoacidosis or 
electrolyte imbalance 
a. Hemolytic anemia with reticulocytosis OR 
b. Leucopenia less than 4.000/rnm3 OR 
c. Lymphopenia less than 1.500/rnm3 OR 
d. Thrombocytopenia less than 100.000/rnm3 
a. Anti-dsDNA: antibody to native DNA in abnormal titer OR 
b. Anti-Sm: presence of antibody to Sm nuclear antigen OR 
c. Positive finding of antiphospholipid antibodies based on: 
(i) an abnormal serum level of IgG or IgM anticardiolipin antibodies 
(ii) a positive test result for lupus anticoagulant using a standard 
method (iii) a false positive test result for at least 6 months and 
confmned by Treponema pallidum inhibition test (TPI) or 
fluorescent treponema! antibody absorption test (FT A) 
An abnormal titer of anti-nuclear antibody by immunofluorescence or 
an equivalent assay at any point in time in the absence of drugs 
(Hochberg, 1997) Arthritis Rheum 40: 1725 
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In the last few years a number of reports have demonstrated the utility of measuring 
antinucleosome autoantibodies in the diagnosis of systemic lupus erythematosus (Amoura 
eta!., 1999) and in drug-induced lupus (Burlingame and Rubin, 1991). Some of the studies 
suggest that anti-nucleosome antibody is a more sensitive test than anti-dsDNA for SLE 
patients (Min et al., 2002 and Cervera eta!., 2003). Anti-nucleosome antibodies have been 
reported in 40% - 80% of SLE, depending on the disease status and in 0% - 15% of other 
autoimmune diseases such as scleroderma, Sjogren's syndrome and rheumatoid arthritis. 
They are rarely found in normal blood donors or patients suffering from infectious diseases 
(Cacoub eta/., 1997 and Suer eta!., 2004). 
1.1.7. Anti-nucleosome antibodies 
Anti-nucleosome antibodies have only recently been highlighted, as they make up the 
majority of antibodies causing lupus erythematosus (LE) cell formation. They were given 
different names over the last few decades e.g., anti-histone (Fritzler and Tan, 1978), LE 
cells factor (Rekvig and Hannestad, 1981 ), anti-deoxyribonucleoprotein (DNP) (Krash et 
al., 1982), Anti-H2A-H2B-DNA (Wallace et a/., 1994), anti-nucleosome (Hmida et al., 
2002) and anti-chromatin (Czaja et a/., 2003). 
In the nucleus of eukaryocytes the native complex of histone and DNA is called chromatin. 
It is comprised of approximately 40% DNA, 40% histones and 20% non histone proteins 
such as RNA and other macromolecules. The periodic arrangement of histone along with 
the DNA gives a "beads-on-a-string" appearance in electron micrographs (Figure 1.1 ). 
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Digesting linker DNA between the "beads" with micrococcal nuclease yield nucleosomes, 
each nucleosome is made up of appro~imately 200 bp of DNA wrapped twice around the 
(H2A-H2B-H3-H4)2 histone octamer, with histone HI bound on the outside (Figure 1.2). 
Non histone and RNA are also bound to some nucleosomes. Whole chromatin is insoluble 
at physiologic ionic strength and contains many nonhistone macromolecules. Since 
nucleosomes are only sparingly soluble, it is difficult to use either whole chromatin or 
nucleosomes in immunoassays. The most useful form of chromatin to be used as an antigen 
in ELISA is solubilized by digestion with micrococcal nuclease while HI and nonhistone 
proteins are removed by extracting the chromatin with 0.5 M NaCl at neutral PH. This 
process yields nucleosome core particle (Figure I.3). 
Polynucleosome core particles, in which the linker DNA is not cut by the nuclease, are 
called HI-stripped chromatin. Interestingly, almost all the studies of "anti-nucleosome" 
and "anti-chromatin" actually used a mixture ofnucleosome core particle and HI- stripped 
chromatin as an antigen in ELISA (Lewin, 2000). 
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Nucleosome "bead" 
(8 histone molecules + 
146 nucleotide pairs of DNA) 
Figure 1.1 The per·iodic arTangement of histone along with the DNA gives a "beads-
on-a-string" appearance Cited f.-om htta>://www.zoolo2Y.ubc.ca/- bio463/lectu•·e 3.htm 
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